This week's BIO CEO conference is the largest conference of publicly traded biotech companies, and in this video, Motley Fool health care bureau chief Brenton Flynn highlights some takeaways from the conference. He discusses Celgene (CELG +0.00%) CEO Bob Hugin's fireside chat at the beginning of the conference, where he told investors about the company's FDA approval for its relapsed/refractory multiple myeloma drug Pomalyst. Hugin also discussed why he doesn't see Onyx's (NASDAQ: ONXX) drug Krypolis to be a direct competitor, and how Celgene intends to maximize the opportunity it has with its top-selling drug, Revlimid.
